The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials

University of Leicester, Leiscester, England, United Kingdom
Blood Pressure Monitoring (Impact Factor: 1.18). 06/2007; 12(3):141-7. DOI: 10.1097/MBP.0b013e3280b10bbd
Source: PubMed

ABSTRACT The period of early morning blood pressure surge is associated with a higher incidence of cardiovascular events than at other times of the day. Antihypertensive medication given once daily in the morning may not protect against this surge if its duration of action is too short. We compared telmisartan, an angiotensin II receptor blocker with a trough-to-peak ratio >90%, with ramipril, an angiotensin-converting enzyme inhibitor with a trough-to-peak ratio of around 50%.
Data from two prospective, randomized, open-label, blinded endpoint studies comparing telmisartan force titrated to 80 mg once daily and ramipril 10 mg once daily were pooled. Patients had mild-to-moderate hypertension and were assessed using 24-h ambulatory blood pressure monitoring at baseline and endpoint. Early morning blood pressure surge was defined as the difference between mean blood pressure within 2 h after arising and night-time low. Patients were grouped into quartiles according to their baseline systolic surge.
Data from 1279 patients were analyzed. Telmisartan changed the overall mean (SE) systolic surge by -1.5 (0.47) mmHg, and ramipril by +0.3 (0.47) mmHg (P=0.0049). The magnitude of surge reduction was greatest in the quartile with highest baseline systolic surge: telmisartan -12.7 (0.91), ramipril -7.8 (1.02) mmHg (P=0.0004). Telmisartan also reduced the surge compared with ramipril in dippers, but there were no differences between the two groups in nondippers.
Telmisartan significantly reduced the early morning systolic blood pressure surge compared with ramipril. A reduction in this surge may help to reduce cardiovascular events in the morning period.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: High 24-h ambulatory blood pressure (ABP) variability is associated with poor cardiovascular outcomes. We analysed a large ABP monitoring database containing data from hypertensive patients treated with telmisartan/amlodipine combination or various monotherapies with the aim of quantifying the 24-h distribution of blood pressure (BP) reduction by treatment through the smoothness index and of developing and testing a new treatment-on-variability index (TOVI) to quantify the effects of treatment on both mean BP and BP variability. ABP data were pooled from 10 studies (N = 4294) with a median follow-up of 60 days. Smoothness index was calculated by dividing the mean of treatment-induced hourly BP reductions by its SD. TOVI was calculated as the ratio of the mean of hourly BP reductions to weighted 24-h BP SD (weighted mean of daytime and night-time SDs) under treatment. The SBP/DBP smoothness index and TOVI values of telmisartan/amlodipine combination were significantly (P < 0.0001) higher (smoothness index: 1.81/1.51; TOVI: 2.71/2.13) compared with telmisartan 80 mg (smoothness index: 1.12/0.90; TOVI: 1.55/1.23), amlodipine 10 mg (smoothness index: 1.33/1.09; TOVI: 2.09/1.58), valsartan 160 mg (smoothness index: 1.01/0.81; TOVI: 1.35/1.07), ramipril 10 mg (smoothness index: 0.83/0.63; TOVI: 1.11/0.87) and placebo (smoothness index: 0.23/0.18; TOVI: 0.34/0.30), indicating a smoother 24-h BP reduction profile (higher smoothness index) as well as the achievement of significantly lower and smoother BP levels over 24 h (higher TOVI) with the combination. As compared with various monotherapies, the telmisartan/amlodipine combination was associated with a smoother BP reduction over 24 h and with a more favourable balance between mean 24-h BP reduction and the degree of BP variability on treatment, reflecting both its effectiveness in lowering BP levels and its longer duration of action. The agreement between smoothness index and TOVI demonstrates that they are similarly effective in the differentiation of antihypertensive treatments, although providing conceptually different information, the clinical relevance of which needs to be tested by ad-hoc outcome studies.
    Journal of Hypertension 04/2014; 32(6). DOI:10.1097/HJH.0000000000000169 · 4.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In-office blood pressure (BP) measurements have recognized limitations, including the inability to collect BP information over a long period of time, and during an individual's usual daily activities. Home or ambulatory BP monitoring (ABPM) may therefore be used to complement conventional office measurements, thereby improving prognostic value. Of particular relevance is the ability of 24 h ABPM to quantify the degree of BP variability over 24 h, which has been shown to be a significant and independent risk factor for cardiovascular (CV) morbidity and mortality. Twenty-four hour BP variability is indeed strongly associated with clinical outcomes, and the ability of ABPM to provide a quantification of BP throughout the 24-h period during an individual's normal daily routine is one of the reasons for its high prognostic value. The smoothness index (SI) provides a useful measure of antihypertensive treatment efficacy over the 24 h dosing period, its values being highest with antihypertensive agents that have large and consistent effects across 24 h. Telmisartan and amlodipine are long-acting antihypertensive drugs that, in combination, not only reduce 24 h mean BP more than the respective monotherapies but also provide a significantly greater SI. The provision of homogeneous 24 h BP control has important clinical implications. Maintaining smooth BP over the entire 24 h dosing period may contribute to the improvement of CV outcomes, and reductions in BP variability may decrease end organ damage, and reduce CV risk.Hypertension Research advance online publication, 5 December 2013; doi:10.1038/hr.2013.145.
    Hypertension Research 12/2013; DOI:10.1038/hr.2013.145 · 2.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Arterial hypertension is a powerful factor of cardiovascular risk, and it usually appears in association with other factors that may worsen its diagnosis and/or increase cardio vascular risk. Through worldwide literature it is well known that a change of lifestyles can provide additional reductions of tensional figures. The main purpose of this study was to show that by using single or combined anti-hypertensive medications in order to reach objectives plus adding some recommendations for changes in the patients' lifestyles, a higher benefit is obtained as to the impact of the goals set or the reduction of the pharmacological therapy. Follow up of 1.605 hypertensive patients was carried out for four months, in a real-life study, thanks to the cooperation of 210 physicians from Colombia's leading cities. They were divided into two groups: the first, the control group, received conventional therapy and, according to the physician's criterion, if necessary, to add 80 mg of telmisartan or telmisartan plus hydrochlorothiazide (HCTZ) (through combination and monotherapy); and the second, or balance group, in addition to the treatment, was given a concrete behavioral intervention through specific recommendations to reduce cardiovascular risk. Average reductions of Systolic Blood Pressure and Diastolic Blood Pressure were evaluated, as well as the achievement of set goals through the additional intervention of changes in lifestyles. The reduction obtained of the (average) systolic blood pressure was of 26.1 mm Hg (SD 16.1) in the balance group, and of 13.98 (SD 9.1) mm HG and 13.37 (SD 9.1) for the corresponding balance and control groups. No meaningful changes were observed between the two groups, but the goals regarding tensional figures in 591 (75.7%) of the control group, and in 635 (77%) of the balance group were achieved. It is concluded that telmisartan alone or in combination with HCTZ or other hypertensive therapies, was effective in the reduction of both systolic and diastolic tensional figures, thus facilitating the achievement of the set goals. The balance group did not show a meaningful statistical outcome, probably because a higher persistence and periodicity are required, and preferably under a personalized education given to the patients so that they change to a healthier lifestyle that has a meaningful impact on their treatment to achieve the objective of a greater reduction of tensional figures.
    06/2011; 19(1):16-22.


Available from
May 21, 2014